Current Uses of Botulinum Neurotoxins in Plastic Surgery

Noland, Marie; Lalonde, Donald H.; Yee, Gilbert; Rohrich, Rod J.

doi:10.1097/prs.0000000000002480

Cited by 17 publications

(13 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many off‐label cosmetic uses of BTA have been introduced . Intradermal injection of BTA was the other technique that has been used off‐label by many clinicians for the purpose of face‐lifting effect.…”

Section: Discussionmentioning

confidence: 99%

The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face‐lifting: a split‐face randomized controlled trial

Wanitphakdeedecha

Ungaksornpairote

Kaewkes

et al. 2016

J of Cosmetic Dermatology

View full text Add to dashboard Cite

SummaryBackground Botulinum toxin type A (BTA) has been approved for the treatment of strabismus, blepharospasm, muscle spasm, cervical dystonia, pain syndrome, glabella wrinkles, and severe primary axillary hyperhidrosis. Intradermal injection of BTA has been used off-label by many clinicians for the purpose of face-lifting effect. Few studies on onabotulinumtoxinA (ONA) demonstrated no clinical efficacy on facelifting effect when comparing to normal saline solution (NSS). So far, there is no split-face comparison study on face-lifting effect of abobotulinumtoxinA (ABO). Objective To determine the face-lifting effect of ABO intradermal injection and NSS. Methods Twenty-two subjects with symmetrical faces on both facial expression and expressionless were randomly injected with ABO at 1:7 cc dilution (500 unit or one vial in 7 cc of NSS) on one side and NSS on the other side using intradermal injection technique. Standardized photographic documentation was obtained at baseline, and at 2 weeks after treatment. The face-lifting effect was graded by two blinded dermatologists using photographic comparison and rated by the patients. Side effects were also recorded at the end of the study. Results Face-lifting effect was demonstrated in 40.9% and 4.5% of patients with ABO and NSS, respectively. There was a statistically significant difference in face-lifting effect when comparing between ABO and NSS (P = 0.021). The face-lifting was reported in 50.0% of patients receiving ABO injection. The patients with oval-face shape tended to respond better with ABO (P = 0.046). The odd of face-lifting effect for patients aged younger than 32 was higher than patients aged older than 32 with the odds ratio of 7.9 and 95% confidence interval of 1.1-56.1. Facial asymmetry was found in 22.7% of subjects. Conclusions This study demonstrated the face-lifting effect of ABO intradermal injection. Patients with oval-face shape and aged younger than 32 tended to respond better. Therefore, patient selection should be emphasized to improve efficacy of this technique.

show abstract

Section: Discussionmentioning

confidence: 99%

The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face‐lifting: a split‐face randomized controlled trial

Wanitphakdeedecha

Ungaksornpairote

Kaewkes

et al. 2016

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…14 It also provides the ability to control sweat and sebaceous glands, providing a smoother skin. 5,17 Studies have confirmed Botox as modality to treat palmar hyperhidrosis.…”

Section: Neurotoxinsmentioning

confidence: 97%

“…4,5 The 3 types are generally constituted in 0.9% sterile, saline (preserved and nonpreserved can be used) with the reconstituted product safely stored for 1 week. The patient’s presentation and treatment areas influence the amount of the product injected.…”

Section: Neurotoxinsmentioning

confidence: 99%

“…5–7 The effects of the neurotoxins last for approximately 3 to 4 months. Adverse complications can arise often because of improper techniques and lack of facial anatomy, leading to pain, inflammation, ecchymosis, erythema, and local weakness.…”

Section: Neurotoxinsmentioning

confidence: 99%

“…18 Other type A products including the Korean versions (Meditoxin/Siax/Neuronox) and Prosigne (Lanzhou Institute of Biological Products, Lanzhou, People’s Republic of China) are currently not approved by the FDA but may be in the future pending future trials. 5 …”

Section: Neurotoxinsmentioning

confidence: 99%

See 2 more Smart Citations

Global Updates on the Future Directions of Neurotoxins and Fillers

Downie

Patel

Heningburg³

2016

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Summary:Neurotoxins and fillers continue to remain in high demand, comprising a large part of the growing business of cosmetic minimally invasive procedures. Multiple Food and Drug Administration–approved safe yet different products exist within each category, and the role of each product continues to expand. The authors review the literature to provide an overview of the use of neurotoxins and fillers and their future directions.

show abstract

Botulinum Toxin Treatment in Plastic Surgery

Noland

Morris

2020

Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine

View full text Add to dashboard Cite

Current Uses of Botulinum Neurotoxins in Plastic Surgery

Cited by 17 publications

References 95 publications

The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face‐lifting: a split‐face randomized controlled trial

The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face‐lifting: a split‐face randomized controlled trial

Global Updates on the Future Directions of Neurotoxins and Fillers

Botulinum Toxin Treatment in Plastic Surgery

Contact Info

Product

Resources

About